Bayer will present new phase III data for its investigational low-dose MRI contrast agent gadoquatrane across various clinical settings at ECR 2026 in Vienna from 4 to 8 March, as well as showcasing new advances in its radiology portfolio.
The firm said that the focus of its scientific sessions will be progress in its development pipeline for contrast agents and injectors, as well as data-driven connectivity tools designed to improve workflows and support informed decisions in radiology.
Phase III subgroup data for gadoquatrane will be presented, underscoring the efficacy and safety of gadoquatrane in abdominal and cardiac MRI and magnetic resonance angiography, as well as new analysis from phase II and phase III studies in central nervous system (CNS) imaging and pharmacokinetics data, the company stated.
Gadoquatrane is an investigational low-dose macrocyclic gadolinium-based contrast agent for contrast-enhanced MRI. Bayer has submitted applications for marketing authorization of gadoquatrane in markets including Japan, the U.S., the EU, and China, with more markets to follow in the next months, Bayer added.
These sessions follow Bayer's announcement of positive topline data for all studies of the phase III QUANTI program in 2025.
